Tests inulin fiber supplement for heart and metabolic health with GLP-1 medicines
Tests inulin fiber supplement in adults with obesity or overweight taking GLP-1 medicines.
Plain-language title generated from the registry record
Registry title: Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA ) Medications for Weight Loss
Key facts
- Where
- Enshi, Shiyan, Wuhan, and Xiangyang, ChinaSee the 5 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Source: NCT07611552, who can take part
Where in China
- The Central Hospital of Enshi Tujia and Miao Autonomous PrefectureEnshi, ChinaNo longer taking part
- Sinopharm Dongfeng General HospitalShiyan, ChinaNo longer taking part
- Huazhong University of Science and TechnologyWuhan, ChinaNo longer taking part
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaNo longer taking part
- Xiangyang No.1 People's HospitalXiangyang, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Huazhong University of Science and Technology
- Trial code
- NCT07611552
- Record updated
- 3 June 2026
- Original description
The goal of this double-blind randomized placebo-controlled supplement study is to investigate if the supplement of inulin (prebiotics, 10 grams per day) has beneficial effects on cardiometabolic risk factors in overweight or obese individuals receiving glucagon-like peptide-1 receptor agonists (GLP-1 RA) medications for weight loss.Read full original descriptionShow less
The Effect of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Medications for Weight Loss: a Randomized Double-blind Controlled Trial
The goal of this double-blind randomized placebo-controlled supplement study is to investigate if the supplement of inulin (prebiotics, 10 grams per day) has beneficial effects on cardiometabolic risk factors in overweight or obese individuals receiving glucagon-like peptide-1 receptor agonists (GLP-1 RA) medications for weight loss.
Inclusion: Be overweight or obese (meeting any of the following criteria):; Obesity: BMI >=28 kg/m²; Overweight (BMI >= 24 kg/m²) with at least one body weight-related comorbidity: obstructive sleep apnea syndrome, prediabetes, type 2 diabetes mellitus, hypertension, dyslipidemia, polycystic ovary syndrome, or non-alcoholic fatty liver disease; Must have received GLP-1 RA drugs (Semaglutide, Liraglutide, Benaglutide, Tirzepatide, or Mazdutide) for weight-loss intervention for at least 3 months, and plan to continue using them for the next six months; Age 18-64 years; Consent to participate and sign the informed consent form.
Exclusion: Currently using non-GLP-1 RA medications for weight-loss, or have undergone or plan to undergo weight-loss procedures within the next 4 months; Be allergic or intolerance to inulin-type substances; Long-term user of prebiotics or probiotics (excluding fermented dairy products such as yogurt); Have participated in in other clinical trials within the past 3 months or are currently participating in other clinical trials; Plan to be pregnant within the next year, are currently pregnant, or are breastfeeding; Deemed unsuitable for participation by the investigator's judgment.